UPCC 16422 Examining Mechanisms of Resistance to CD20-directed Therapy in Patients with Lymphoma

Enrolling By Invitation
99 years or below
All
Phase N/A
20 participants needed
1 Location

Brief description of study

To determine potential mechanisms of CD20 loss after CD20-directed therapy in non-Hodgkin lymphomas.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 22 Apr 2026. Study ID: 22-0423
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator